10-Q: Seer Inc. Reports Third Quarter 2024 Results: Revenue Mixed Amidst Cost-Cutting Measures

Seer Inc. reported a mixed third quarter with a slight decrease in revenue, offset by cost-cutting measures and a net loss of $21.3 million.

Summary

• Seer Inc. reported a net loss of $21.3 million for the third quarter of 2024, compared to a net loss of $21.1 million in the same period of 2023.
• Total revenue for the quarter was $4.03 million, a slight decrease from $4.16 million in the third quarter of 2023, primarily due to a decrease in grant revenue.
• Product revenue increased by 58% to $2.9 million, while service revenue increased by 23% to $0.66 million.
• Related party revenue decreased by 74% to $0.37 million, and grant and other revenue decreased by 74% to $0.09 million.
• The company's cost of revenue increased by 4% to $2.09 million, primarily due to higher instrument sales.
• Operating expenses decreased by 6% to $26.3 million, driven by lower headcount and stock-based compensation.
• Research and development expenses decreased by 2% to $13.0 million, while selling, general, and administrative expenses decreased by 10% to $13.3 million.
• The company's cash and cash equivalents and short-term investments totaled $247.6 million as of September 30, 2024.
• The company believes its current cash and investments are sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive growth in product and service revenue, but also a decrease in total revenue and continued net losses. The company's cost-cutting measures and strong cash position are positive, but the risks and uncertainties remain significant.

Positives

• The company experienced strong growth in product and service revenue, indicating increasing market adoption.
• Cost-cutting measures led to a reduction in operating expenses, improving the company's financial position.
• The company has a substantial amount of cash and investments, providing a financial runway for at least the next twelve months.
• The company is actively managing its capital structure through a share repurchase program.

Negatives

• Total revenue decreased slightly due to a significant drop in related party and grant revenue.
• The company continues to incur significant net losses, with a loss of $21.3 million for the quarter.
• The company's reliance on a small number of customers, including a related party, poses a risk to revenue stability.
• The company's investment in PrognomiQ resulted in a loss of $0.86 million.

Risks

• The company's ability to achieve profitability depends on the successful commercialization of the Proteograph Product Suite.
• The company faces competition from other life sciences technology companies.
• The company relies on single suppliers for some components of its products, which could disrupt supply chains.
• The company's products could have defects or errors, leading to claims and reputational damage.
• The company's international business exposes it to various risks, including regulatory and political uncertainties.
• The company's intellectual property may not be adequately protected, and it may face infringement claims.
• The company's stock price may be volatile and subject to market fluctuations.
• The company's ability to use net operating losses to offset future taxable income may be limited.

Future Outlook

The company expects to continue to incur significant losses and does not expect positive cash flows from operations for the foreseeable future. However, the company believes its current cash and investments are sufficient to fund operations for at least the next twelve months.

Management Comments

• Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.
• The Company believes that its cash and cash equivalents and investments as of September 30, 2024 provide sufficient capital resources to continue its operations for at least twelve months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Industry Context

The company operates in the competitive life sciences technology market, facing competition from established players and emerging companies in the proteomics and genomics fields. The company's success depends on its ability to gain market acceptance for its Proteograph Product Suite and to develop new products and services that meet customer needs.

Comparison to Industry Standards

• While specific benchmarks for proteomics companies are still developing, Seer's revenue growth in product and service areas is a positive sign compared to some peers in the early commercialization phase.
• The company's cost-cutting measures are in line with industry trends for companies seeking to improve profitability.
• The company's cash position is relatively strong compared to other early-stage life sciences companies, providing a buffer for future operations.
• Companies like Agilent Technologies, Bruker Corporation, and Thermo Fisher Scientific are established competitors with broader product lines and greater resources, while companies like Nautilus Biotechnology and Olink Proteomics are more direct competitors in the proteomics space.

Legal Proceedings

• The Company had accrued legal contingencies of $1.3 million, recorded within accrued expenses in the unaudited condensed consolidated balance sheets.
• On December 28, 2023, Giulio Caracciolo and Dipartimento di Medicina Molecolare Sapienza Universita di Roma filed a lawsuit against us, BWH, and other inventors in the United States District Court for the Northern District of California (Case No. 4:23-cv-06643). That lawsuit was dismissed with prejudice on October 25, 2024, pursuant to a stipulation of dismissal.

Related Party Transactions

• For the three and nine months ended September 30, 2024, the Company recognized revenue from a related party that represented 14 % and 20 % , respectively, of the Companys total revenue.
• For the three and nine months ended September 30, 2023, the Company recognized revenue from this same related party that represented 34 % and 33 % , respectively, of the Company's total revenue.
• As of each of September 30, 2024 and December 31, 2023, the Company recorded $ 0.6 million in related party receivables, on the condensed consolidated balance sheets mainly due from product sales and services revenue.
• On August 12, 2024, the Company entered into a preferred stock purchase agreement with PrognomiQ, pursuant to which the Company purchased $ 10.0 million of PrognomiQ's Series D Preferred Stock.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the slight decrease in total revenue.
• Employees may be affected by the cost-cutting measures, including potential reductions in force.
• Customers may benefit from the company's focus on product and service improvements.
• Suppliers may be impacted by the company's efforts to manage costs and supply chains.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• The company will continue to focus on commercializing the Proteograph Product Suite.
• The company will continue to build its sales, marketing, service, support and distribution infrastructure.
• The company will continue to engage in research and development of other products and enhancements to the Proteograph Product Suite.
• The company will continue to implement operational, financial and management information systems.

Key Dates

Keywords

Proteomics, Proteograph Product Suite, Life Sciences, Commercialization, Revenue, Net Loss, Operating Expenses, Share Repurchase, Financial Results, Investments